Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes

Metabolism: Clinical and Experimental

Volumn 47, Issue 6, 1998, Pages 637-643

  Panahloo, A ^a,b   Mohamed Ali, V ^a   Andres C ^a   Denver, A E ^a   Yudkin, J S ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; CHOLESTEROL; GLIBENCLAMIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN INSULIN; HUMULIN M3; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROINSULIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; FIBRINOLYSIS; HUMAN; INSULIN TREATMENT; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

EID: 0031750031     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(98)90023-3     Document Type: Article

References (36)

1. Pirart J: Diabetes mellitus and its degenerative complications: A prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1:252-263, 1987
2. Taskinen MR, Kuusi T, Helve E, et al: Insulin therapy induces antiatherogenic changes of serum lipoproteins in non-insulin dependent diabetes. Arteriosclerosis 8:168-177, 1988
3. Yudkin JS: Circulating proinsulin-like molecules. J Diabetes Complications 7:113-123, 1993
4. Nagi DK, Rendra TJ, Ryle AJ, et al: The relationship of concentrations of insulin, intact proinsulin and 32,33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 33:532-537, 1990
5. Auwerx J, Bouillon R, Collen D, et al: Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 8:68-72, 1988
6. Hamsten A, Wiman B, De Faire U, et al: Increased plasma level of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 40:113-121, 1985
7. Alessi MC, Juhan-Vague I, Kooistra T, et al: Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line HepG2. Thromb Haemost 60:491-494, 1988
8. Nordt T, Schneider D, Sobel E: Augmentation of synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease. Circulation 89:321-330, 1994
9. Stiko-Rahm A, Wiman B, Hamsten A, et al: Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein cells is induced by very low density lipoprotein. Arteriosclerosis 10:1067-1073, 1990
10. Nordt TK, Klassen JK, Schneider DJ, et al: Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implication for local fibrinolysis. Arterioscler Thromb 13:1822-1828, 1993
11. Nordt T, Sawa H, Fujii S, et al: Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 91:764-770, 1995
12. Panahloo A, Mohamed-Ali V, Lane A, et al: Determinants of PAI-1 activity in treated type 2 diabetes and its relation to a polymorphism in the PAI-1 gene. Diabetes 44:37-42, 1995
13. Nagi DK, Yudkin JS: Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 16:621-629, 1993
14. Jain SK, Nagi DK, Slavin BM, et al: Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabet Med 10:27-32, 1993
15. World Health Organization: Diabetes mellitus: Report of a WHO Study Group. World Health Organ Tech Rep Ser 727:9-20, 1985
16. Harano Y, Ohgaku S, Hidaka H, et al: Glucose, insulin and somatostatin infusion for the determination of insulin sensitivity. J Clin Endocrinol Metab 45:1124-1127, 1977
17. Heine RJ, Home PD, Poncher M, et al: A comparison of 3 methods for assessing insulin sensitivity in subjects with normal and abnormal glucose tolerance. Diabetes Res 2:113-120, 1985
18. Mohamed-Ali V, Gould MM, Gillies S, et al: Associations of proinsulin-like molecules with lipids and fibrinogen in non-diabetic subjects - Evidence against a modulating role for insulin. Diabetologia 38:1110-1116, 1995
19. Chesham J, Anderton SW, Kingdom CFM: Rapid competitive enzymoimmunoassay for albumin in urine. Clin Chem 32:669-671, 1986
20. Fleiss JL: The Design and Analysis of Clinical Experiments: The Crossover Study. Wiley, New York, NY, 1986, pp 263-290
21. Hills M, Armitage P: The two-period cross-over trial. Br J Clin Pharmacol 8:7-20, 1979
22. Galloway JA: Treatment of NIDDM with insulin agonists or substitutes. Diabetes Care 13:1209-1239, 1990
23. University Group Diabetes Program: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 19:747-830, 1970 (suppl 2)
24. Gram J, Kold A, Jespersen J: Rise in plasma t-PA fibrinolytic activity in a group of maturity onset diabetic patients shifted from a first generation (tolbutamide) to a second generation sulphonylurea (gliclazide). J Intern Med 225:241-247, 1989
25. Hamsten A, De Faire U, Walldius G, et al: Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 2:3-9, 1987
26. Malmberg K, Rydén L, Hamsten A, et al: Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. Eur Heart J 17:1337-1344, 1996
27. Malmberg K, for the DIGAMI Study Group: Prospective randomised study of intensive insulin treatment on long term survival after myocardial infarction in patients with diabetes mellitus. BMJ 314:1512-1514, 1997
28. Grant PJ, Kruithof EKO, Felly CP, et al: Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man. Clin Sci 79:513-516, 1990
29. McCormack L, Strickland MH, Grant PJ: Plasminogen activator inhibitor-1 antigen concentrations during insulin and oral glucose tolerance tests in obese man. Fibrinolysis 7:225-228, 1993
30. Nagi DK, Tracy R, Pratley R: Relationship of hepatic and peripheral insulin resistance with PAI-1 in Pima Indians. Metabolism 45:1243-1247, 1996
31. Seljeflot I, Eritsland J, Torjesen P, et al: Insulin and PAI-1 levels during oral glucose tolerance test in patients with coronary heart disease. Scand J Clin Lab Invest 54:241-246, 1994
32. Declerck PJ, Verstreken M, Collen D: Measurement of different forms of plasminogen activator inhibitor-1 (PAI-1) using various monoclonal antibody based enzyme-linked immunosorbent assays. Fibrinolysis 4:132-133, 1990 (suppl 2)
33. Chandler WL, Alessi MC, Aillaud MF, et al: Clearance of tPA antigen in patients with high PAI-1 activity levels. Circulation 96:761-768, 1997
34. Andreotti F, de Bart CW, Regan T: Factors affecting the relationship between PAI-1 activity and PAI-1 antigen levels in normals and in patients with arterial disease. Fibrinolysis 4:134-135, 1990 (suppl 2)
35. Alessi MC, Juhan-Vague I, Declerck PJ, et al: Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels. Thromb Res 60:509-516, 1990
36. UK Prospective Diabetes Study Group: UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 34:877-890, 1991